Mingdong Huang

List of Publications by Year in Descending Order

195 papers	6,635 citations	40 h-index	75 g-index
208 ext. papers	7,449 ext. citations	6.1 avg, IF	5.61 L-index

#	Paper	IF	Citations
195	A Clot-Homing Near-Infrared Probe for In Vivo Imaging of Murine Thromboembolic Models.. *Advanced Healthcare Materials*, **2022**, e2102213	10.1	0
194	A versatile insertion point on albumin to accommodate peptides and maintain their activities.. *International Journal of Biological Macromolecules*, **2022**, 205, 49-49	7.9	0
193	Crystal structure and cellular functions of uPAR dimer.. *Nature Communications*, **2022**, 13, 1665	17.4	2
192	Functionalized zinc oxide microparticles for improving the antimicrobial effects of skin-care products and wound-care medicines **2022**, 212728		0
191	Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments. *Future Medicinal Chemistry*, **2021**, 0	4.1	0
190	Expanding the applications of photodynamic therapy-tooth bleaching. *Clinical Oral Investigations*, **2021**, 1	4.2	0
189	Vascular thiol isomerases: Structures, regulatory mechanisms, and inhibitor development. *Drug Discovery Today*, **2021**, 27, 626-626	8.8	1
188	Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. *Drug Discovery Today*, **2021**, 26, 1076-1085	8.8	12
187	Synergy and allostery in ligand binding by HIV-1 Nef. *Biochemical Journal*, **2021**, 478, 1525-1545	3.8	2
186	Using porphyrins as albumin-binding molecules to enhance antitumor efficacies and reduce systemic toxicities of antimicrobial peptides. *European Journal of Medicinal Chemistry*, **2021**, 217, 113382	6.8	2
185	A supramolecular nanocarrier for efficient cancer imaging and therapy by targeting at matriptase. *Journal of Controlled Release*, **2021**, 334, 153-163	11.7	1
184	Development of a Potent Antimicrobial Peptide With Photodynamic Activity. *Frontiers in Microbiology*, **2021**, 12, 624465	5.7	1
183	Unveiling the molecular mechanism of pH-dependent interactions of human serum albumin with chemotherapeutic agent doxorubicin: A combined spectroscopic and constant-pH molecular dynamics study. *Journal of Molecular Liquids*, **2021**, 333, 115949	6	3
182	A strategy for enhanced tumor targeting of photodynamic therapy based on Escherichia coli-driven drug delivery system. *Science China Materials*, **2021**, 64, 232-240	7.1	6
181	Serum Levels of Soluble Platelet Endothelial Cell Adhesion Molecule 1 in COVID-19 Patients Are Associated With Disease Severity. *Journal of Infectious Diseases*, **2021**, 223, 178-179	7	13
180	A general strategy to inhibit serine protease by targeting its autolysis loop. *FASEB Journal*, **2021**, 35, e21259	0.9	6
179	Regulation of pro-□activation: a key checkpoint in Bacillus subtilis sporulation. *Environmental Microbiology*, **2021**, 23, 2366-2373	5.2	0

178	Novel pH-Triggered Doxorubicin-Releasing Nanoparticles Self-Assembled by Functionalized β-Cyclodextrin and Amphiphilic Phthalocyanine for Anticancer Therapy. *ACS Applied Materials & Interfaces*, **2021**, 13, 10674-10688	9.5	9
177	Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat. *Journal of Virology*, **2021**, 95, e0086121	6.6	5
176	Dual effects of quercetin on protein digestion and absorption in the digestive tract. *Food Chemistry*, **2021**, 358, 129891	8.5	4
175	Potent inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 by photosensitizers compounds. *Dyes and Pigments*, **2021**, 194, 109570	4.6	2
174	Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA).. *Journal of Medicinal Chemistry*, **2021**,	8.3	1
173	Inhibition of the Citrus Canker Pathogen Using a Photosensitizer Assisted by Sunlight Irradiation. *Frontiers in Microbiology*, **2020**, 11, 571691	5.7	4
172	Suppression of cancer proliferation and metastasis by a versatile nanomedicine integrating photodynamic therapy, photothermal therapy, and enzyme inhibition. *Acta Biomaterialia*, **2020**, 113, 541-553	10.8	4
171	Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain. *International Journal of Biological Sciences*, **2020**, 16, 981-993	11.2	3
170	Therapeutics targeting the fibrinolytic system. *Experimental and Molecular Medicine*, **2020**, 52, 367-379	12.8	34
169	Naftifine enhances photodynamic therapy against Staphylococcus aureus by inhibiting staphyloxanthin expression. *Dyes and Pigments*, **2020**, 179, 108392	4.6	4
168	Photocyanine: A novel and effective phthalocyanine-based photosensitizer for cancer treatment. *Journal of Innovative Optical Health Sciences*, **2020**, 13, 2030009	1.2	17
167	Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases. *Bioscience, Biotechnology and Biochemistry*, **2020**, 84, 1153-1159	2.1	1
166	Tumor Targeting Chemo- and Photodynamic Therapy Packaged in Albumin for Enhanced Anti-Tumor Efficacy. *International Journal of Nanomedicine*, **2020**, 15, 151-167	7.3	7
165	Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells. *Experimental Cell Research*, **2020**, 391, 111987	4.2	5
164	Plasma levels of the active form of suPAR are associated with COVID-19 severity. *Critical Care*, **2020** , 24, 704	10.8	8
163	Small Peptides as Modulators of Serine Proteases. *Current Medicinal Chemistry*, **2020**, 27, 3686-3705	4.3	1
162	Enhanced Antitumor Efficacy and Imaging Application of Photosensitizer-Formulated Paclitaxel. *ACS Applied Materials & Interfaces*, **2020**, 12, 4221-4230	9.5	6
161	A nanometer-sized protease inhibitor for precise cancer diagnosis and treatment. *Journal of Materials Chemistry B*, **2020**, 8, 504-514	7.3	3

160	Photo-triggered release of doxorubicin from liposomes formulated by amphiphilic phthalocyanines for combination therapy to enhance antitumor efficacy. *Journal of Materials Chemistry B*, **2020**, 8, 8022-8036	7.3	7
159	Embelin ameliorated sepsis-induced disseminated intravascular coagulation intensities by simultaneously suppressing inflammation and thrombosis. *Biomedicine and Pharmacotherapy*, **2020**, 130, 110528	7.5	3
158	Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a. *Life Sciences*, **2020**, 246, 117404	6.8	1
157	Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA.. *RSC Advances*, **2020**, 10, 34517-34526	3.7	5
156	Effects of hydroxyl radicals produced by a zinc phthalocyanine photosensitizer on tumor DNA. *Dyes and Pigments*, **2020**, 173, 107894	4.6	7
155	Tumor-targeting photodynamic therapy based on folate-modified polydopamine nanoparticles. *International Journal of Nanomedicine*, **2019**, 14, 6799-6812	7.3	22
154	Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors. *Cancer and Metastasis Reviews*, **2019**, 38, 507-524	9.6	11
153	Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides. *Journal of Medicinal Chemistry*, **2019**, 62, 2172-2183	8.3	8
152	A novel ELISA for the detection of active form of plasminogen activator inhibitor-1 based on a highly specific trapping agent. *Analytica Chimica Acta*, **2019**, 1053, 98-104	6.6	6
151	Expression and purification of recombinant serine protease domain of human coagulation factor XII in. *Bioscience, Biotechnology and Biochemistry*, **2019**, 83, 1815-1821	2.1	3
150	Composite of silver nanoparticles and photosensitizer leads to mutual enhancement of antimicrobial efficacy and promotes wound healing. *Chemical Engineering Journal*, **2019**, 374, 1373-1381	14.7	24
149	Crystal structure of the unoccupied murine urokinase-type plasminogen activator receptor (uPAR) reveals a tightly packed DII-DIII unit. *FEBS Letters*, **2019**, 593, 1236-1247	3.8	4
148	Structural determination of group A Streptococcal surface dehydrogenase and characterization of its interaction with urokinase-type plasminogen activator receptor. *Biochemical and Biophysical Research Communications*, **2019**, 510, 539-544	3.4	
147	Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release. *Theranostics*, **2019**, 9, 884-899	12.1	17
146	A series of photosensitizers with incremental positive electric charges for photodynamic antitumor therapy.. *RSC Advances*, **2019**, 9, 24560-24567	3.7	3
145	Solution Structure of SpoIVB Reveals Mechanism of PDZ Domain-Regulated Protease Activity. *Frontiers in Microbiology*, **2019**, 10, 1232	5.7	2
144	Structural basis of sequence-specific Holliday junction cleavage by MOC1. *Nature Chemical Biology*, **2019**, 15, 1241-1248	11.7	10
143	Crystal structure, epitope, and functional impact of an antibody against a superactive FVIIa provide insights into allosteric mechanism. *Research and Practice in Thrombosis and Haemostasis*, **2019**, 3, 412-419	5.1	

142	6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 126753	2.9	10
141	tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity. *Thrombosis and Haemostasis*, **2019**, 119, 77-86	7	2
140	An efficient synergistic cancer therapy by integrating cell cycle inhibitor and photosensitizer into polydopamine nanoparticles. *Journal of Materials Chemistry B*, **2018**, 6, 2620-2629	7.3	9
139	A novel purification procedure for recombinant human serum albumin expressed in Pichia pastoris. *Protein Expression and Purification*, **2018**, 149, 37-42	2	8
138	Smart Photosensitizer: Tumor-Triggered Oncotherapy by Self-Assembly Photodynamic Nanodots. *ACS Applied Materials & Interfaces*, **2018**, 10, 15369-15380	9.5	20
137	Probing the interactions of phthalocyanine-based photosensitizers with model phospholipid bilayer by molecular dynamics simulations. *Journal of Porphyrins and Phthalocyanines*, **2018**, 22, 764-770	1.8	9
136	The CD163 long-range scavenger receptor cysteine-rich repeat: expression, purification and X-ray crystallographic characterization. *Acta Crystallographica Section F, Structural Biology Communications*, **2018**, 74, 322-326	1.1	2
135	Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition. *Biochimica Et Biophysica Acta - General Subjects*, **2018**, 1862, 2017-2023	4	3
134	Household light source for potent photo-dynamic antimicrobial effect and wound healing in an infective animal model. *Biomedical Optics Express*, **2018**, 9, 1006-1019	3.5	12
133	Dissociation of zinc phthalocyanine aggregation on bacterial surface is key for photodynamic antimicrobial effect. *Journal of Porphyrins and Phthalocyanines*, **2018**, 22, 925-934	1.8	17
132	Crystal structure of plasma kallikrein reveals the unusual flexibility of the S1 pocket triggered by Glu217. *FEBS Letters*, **2018**, 592, 2658-2667	3.8	4
131	Molecular basis of rutin inhibition of protein disulfide isomerase (PDI) by combined and experimental methods.. *RSC Advances*, **2018**, 8, 18480-18491	3.7	6
130	6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer. *Journal of Medicinal Chemistry*, **2018**, 61, 8299-8320	8.3	32
129	Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases.. *RSC Advances*, **2018**, 8, 28189-28197	3.7	7
128	Novel pH-sensitive zinc phthalocyanine assembled with albumin for tumor targeting and treatment. *International Journal of Nanomedicine*, **2018**, 13, 7681-7695	7.3	16
127	Enhanced anti-microbial effect through cationization of a mono-triazatricyclodecane substituted asymmetric phthalocyanine. *Journal of Inorganic Biochemistry*, **2018**, 189, 192-198	4.2	9
126	Phthalocyanine-based photosensitizer with tumor-pH-responsive properties for cancer theranostics. *Journal of Materials Chemistry B*, **2018**, 6, 6080-6088	7.3	13
125	Insights into the binding mechanism of BODIPY-based photosensitizers to human serum albumin: A combined experimental and computational study. *Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy*, **2018**, 203, 158-165	4.4	7

124	Near-infrared-triggered antibacterial and antifungal photodynamic therapy based on lanthanide-doped upconversion nanoparticles. *Nanoscale*, **2018**, 10, 15485-15495	7.7	65
123	Dual antimicrobial actions on modified fabric leads to inactivation of drug-resistant bacteria. *Dyes and Pigments*, **2017**, 140, 236-243	4.6	22
122	Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction. *Biochemistry*, **2017**, 56, 1768-1784	3.2	14
121	Rapid killing of bacteria by a new type of photosensitizer. *Applied Microbiology and Biotechnology*, **2017**, 101, 4691-4700	5.7	29
120	Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator. *Scientific Reports*, **2017**, 7, 3385	4.9	22
119	An effective zinc phthalocyanine derivative against multidrug-resistant bacterial infection. *Journal of Porphyrins and Phthalocyanines*, **2017**, 21, 205-210	1.8	9
118	A structural mechanism of flavonoids in inhibiting serine proteases. *Food and Function*, **2017**, 8, 2437-2443	3.1	27
117	The crystal structure of a multidomain protease inhibitor (HAI-1) reveals the mechanism of its auto-inhibition. *Journal of Biological Chemistry*, **2017**, 292, 8412-8423	5.4	7
116	Recombinant hepatocyte growth factor activator inhibitor 1: expression in Drosophila S2 cells, purification and crystallization. *Acta Crystallographica Section F, Structural Biology Communications*, **2017**, 73, 45-50	1.1	1
115	Photodynamic Oncotherapy Mediated by Gonadotropin-Releasing Hormone Receptors. *Journal of Medicinal Chemistry*, **2017**, 60, 8667-8672	8.3	13
114	Expression and crystallographic studies of the D1D2 domains of C4.4A, a homologous protein to the urokinase receptor. *Acta Crystallographica Section F, Structural Biology Communications*, **2017**, 73, 486-490	1.1	1
113	A long-acting PAI-1 inhibitor reduces thrombus formation. *Thrombosis and Haemostasis*, **2017**, 117, 1338-1347	7	20
112	Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors. *International Journal of Biological Sciences*, **2017**, 13, 1222-1233	11.2	8
111	Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials. *Nanotheranostics*, **2017**, 1, 346-357	5.6	56
110	A Molecular Combination of Zinc(II) Phthalocyanine and Tamoxifen Derivative for Dual Targeting Photodynamic Therapy and Hormone Therapy. *Journal of Medicinal Chemistry*, **2017**, 60, 6693-6703	8.3	40
109	The Crystal Structure of the Fifth Scavenger Receptor Cysteine-Rich Domain of Porcine CD163 Reveals an Important Residue Involved in Porcine Reproductive and Respiratory Syndrome Virus Infection. *Journal of Virology*, **2017**, 91,	6.6	33
108	A Perspective on Reagent Diversity and Non-covalent Binding of Reactive Carbonyl Species (RCS) and Effector Reagents in Non-enzymatic Glycation (NEG): Mechanistic Considerations and Implications for Future Research. *Frontiers in Chemistry*, **2017**, 5, 39	5	8
107	13 Tumor-specific imaging and photodynamic therapy targeting the urokinase receptor. *Series in Cellular and Clinical Imaging*, **2017**, 259-274		

106	Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor. *Angewandte Chemie*, **2016**, 128, 3706-3710	3.6	15
105	Dimer conformation of soluble PECAM-1, an endothelial marker. *International Journal of Biochemistry and Cell Biology*, **2016**, 77, 102-108	5.6	8
104	Sub-5 nm lanthanide-doped lutetium oxyfluoride nanoprobes for ultrasensitive detection of prostate specific antigen. *Chemical Science*, **2016**, 7, 2572-2578	9.4	63
103	Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate. *Biochimica Et Biophysica Acta - General Subjects*, **2016**, 1860, 599-606	4	5
102	Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1. *Data in Brief*, **2016**, 6, 550-5	1.2	2
101	Photodynamic antimicrobial chemotherapy using zinc phthalocyanine derivatives in treatment of bacterial skin infection. *Journal of Biomedical Optics*, **2016**, 21, 18001	3.5	21
100	A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior. *Journal of Biological Chemistry*, **2016**, 291, 15156-68	5.4	26
99	Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor. *Angewandte Chemie - International Edition*, **2016**, 55, 3642-6	16.4	43
98	An ELISA method detecting the active form of suPAR. *Talanta*, **2016**, 160, 205-210	6.2	6
97	A substrate-driven allosteric switch that enhances PDI catalytic activity. *Nature Communications*, **2016**, 7, 12579	17.4	69
96	Crystal structures of the ligand-binding region of uPARAP: effect of calcium ion binding. *Biochemical Journal*, **2016**, 473, 2359-68	3.8	10
95	A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase. *Journal of Cellular and Molecular Medicine*, **2016**, 20, 1851-60	5.6	20
94	Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation. *Journal of Molecular Biology*, **2015**, 427, 1389-1403	6.5	22
93	Quercetin-3-rutinoside Inhibits Protein Disulfide Isomerase by Binding to Its bx Domain. *Journal of Biological Chemistry*, **2015**, 290, 23543-52	5.4	57
92	Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues. *International Journal of Biochemistry and Cell Biology*, **2015**, 62, 88-92	5.6	2
91	Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1. *Journal of Biological Chemistry*, **2015**, 290, 25795-804	5.4	28
90	Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography. *Data in Brief*, **2015**, 5, 107-13	1.2	9
89	A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging. *Acta Biomaterialia*, **2015**, 23, 116-126	10.8	12

88	Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide-Protease Fusions. *Journal of Molecular Biology*, **2015**, 427, 3110-22	6.5	9
87	Lanthanide-doped luminescent nano-bioprobes for the detection of tumor markers. *Nanoscale*, **2015**, 7, 4274-90	7.7	93
86	Spatioselective Fabrication of Highly Effective Antibacterial Layer by Surface-Anchored Discrete Metal□rganic Frameworks. *Advanced Materials Interfaces*, **2015**, 2, 1400405	4.6	16
85	Both platelet- and endothelial cell-derived ERp5 support thrombus formation in a laser-induced mouse model of thrombosis. *Blood*, **2015**, 125, 2276-85	2.2	51
84	Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. *Blood*, **2015**, 125, 1976-85	2.2	58
83	Multifunctional Nano-Bioprobes Based on Rattle-Structured Upconverting Luminescent Nanoparticles. *Angewandte Chemie*, **2015**, 127, 8026-8030	3.6	13
82	Multifunctional Nano-Bioprobes Based on Rattle-Structured Upconverting Luminescent Nanoparticles. *Angewandte Chemie - International Edition*, **2015**, 54, 7915-9	16.4	136
81	Interpreted Recognition Process: A Highly Sensitive and Selective Luminescence Chemosensor. *Chemistry - A European Journal*, **2015**, 21, 11767-72	4.8	18
80	Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo. *International Journal of Nanomedicine*, **2015**, 10, 5327-42	7.3	15
79	Phthalocyanine-Biomolecule Conjugated Photosensitizers for Targeted Photodynamic Therapy and Imaging. *Current Drug Metabolism*, **2015**, 16, 816-32	3.5	24
78	Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor. *Journal of Medicinal Chemistry*, **2015**, 58, 8868-76	8.3	16
77	Expression and crystallographic studies of the ligand-binding region of the human endocytic collagen receptor uPARAP. *Acta Crystallographica Section F, Structural Biology Communications*, **2015**, 71, 1442-7	1.1	2
76	Heavy atom enhanced generation of singlet oxygen in novel indenofluorene-based two-photon absorbing chromophores for photodynamic therapy. *Dyes and Pigments*, **2015**, 117, 7-15	4.6	15
75	Structure and enzymatic activities of human serum albumin. *Current Pharmaceutical Design*, **2015**, 21, 1831-6	3.3	19
74	Evaluation of interactions between urokinase plasminogen and inhibitors using molecular dynamic simulation and free-energy calculation. *Journal of Physical Chemistry A*, **2014**, 118, 9113-9	2.8	9
73	Lanthanide-doped upconversion nanoparticles electrostatically coupled with photosensitizers for near-infrared-triggered photodynamic therapy. *Nanoscale*, **2014**, 6, 8274-82	7.7	121
72	Lanthanide-doped LiLuF(4) upconversion nanoprobes for the detection of disease biomarkers. *Angewandte Chemie - International Edition*, **2014**, 53, 1252-7	16.4	357
71	Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy. *Acta Biomaterialia*, **2014**, 10, 4257-68	10.8	49

70	Dissolution-enhanced luminescent bioassay based on inorganic lanthanide nanoparticles. *Angewandte Chemie - International Edition*, **2014**, 53, 12498-502	16.4	30
69	Lanthanide-Doped LiLuF4 Upconversion Nanoprobes for the Detection of Disease Biomarkers. *Angewandte Chemie*, **2014**, 126, 1276-1281	3.6	30
68	A novel tumor targeting drug carrier for optical imaging and therapy. *Theranostics*, **2014**, 4, 642-59	12.1	54
67	Dissolution-Enhanced Luminescent Bioassay Based on Inorganic Lanthanide Nanoparticles. *Angewandte Chemie*, **2014**, 126, 12706-12710	3.6	12
66	A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility. *PLoS ONE*, **2014**, 9, e115872	3.7	18
65	An effective zinc phthalocyanine derivative for photodynamic antimicrobial chemotherapy. *Journal of Luminescence*, **2014**, 152, 103-107	3.8	36
64	Design, synthesis, and SAR of embelin analogues as the inhibitors of PAI-1 (plasminogen activator inhibitor-1). *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 2379-82	2.9	9
63	ML359, a Small Molecule Inhibitor of Protein Disulfide Isomerase That Prevents Thrombus Formation and Inhibits Oxidoreductase but Not Transnitrosylase Activity. *Blood*, **2014**, 124, 2880-2880	2.2	2
62	Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (M). *PLoS ONE*, **2014**, 9, e85349	3.7	24
61	Regulation of Protein Disulfide Isomerase By S-Nitrosylation Controls Its Function during Thrombus Formation. *Blood*, **2014**, 124, 93-93	2.2	
60	Sub-10 nm Lanthanide-Doped CaF2 Nanoprobes for Time-Resolved Luminescent Biodetection. *Angewandte Chemie*, **2013**, 125, 6803-6808	3.6	37
59	Structural mechanism of ring-opening reaction of glucose by human serum albumin. *Journal of Biological Chemistry*, **2013**, 288, 15980-7	5.4	77
58	Structural insight into inactivation of plasminogen activator inhibitor-1 by a small-molecule antagonist. *Chemistry and Biology*, **2013**, 20, 253-61		28
57	Lanthanide-doped NaScF4 nanoprobes: crystal structure, optical spectroscopy and biodetection. *Nanoscale*, **2013**, 5, 6430-8	7.7	70
56	Rezymogenation of active urokinase induced by an inhibitory antibody. *Biochemical Journal*, **2013**, 449, 161-6	3.8	20
55	Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1. *Journal of Biological Chemistry*, **2013**, 288, 11155-64	5.4	28
54	Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action. *ChemBioChem*, **2013**, 14, 2179-88	3.8	16
53	Sub-10 nm lanthanide-doped CaF2 nanoprobes for time-resolved luminescent biodetection. *Angewandte Chemie - International Edition*, **2013**, 52, 6671-6	16.4	168

52	Detection of active matriptase using a biotinylated chloromethyl ketone peptide. *PLoS ONE*, **2013**, 8, e77146	3.7	14
51	Protein disulfide isomerase capture during thrombus formation in vivo depends on the presence of β3 integrins. *Blood*, **2012**, 120, 647-55	2.2	100
50	Structural evidence of perfluorooctane sulfonate transport by human serum albumin. *Chemical Research in Toxicology*, **2012**, 25, 990-2	4	66
49	Amine-functionalized lanthanide-doped zirconia nanoparticles: optical spectroscopy, time-resolved fluorescence resonance energy transfer biodetection, and targeted imaging. *Journal of the American Chemical Society*, **2012**, 134, 15083-90	16.4	203
48	Crystal structure of the urokinase receptor in a ligand-free form. *Journal of Molecular Biology*, **2012**, 416, 629-41	6.5	41
47	Amine-functionalized lanthanide-doped KGdF4 nanocrystals as potential optical/magnetic multimodal bioprobes. *Journal of the American Chemical Society*, **2012**, 134, 1323-30	16.4	353
46	Enhanced photodynamic efficacy of zinc phthalocyanine by conjugating to heptalysine. *Bioconjugate Chemistry*, **2012**, 23, 2168-72	6.3	37
45	Structural recognition mechanisms between human Src homology domain 3 (SH3) and ALG-2-interacting protein X (Alix). *FEBS Letters*, **2012**, 586, 1759-64	3.8	7
44	Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains. *Journal of Biological Chemistry*, **2012**, 287, 27526-36	5.4	7
43	Receptor-targeting phthalocyanine photosensitizer for improving antitumor photocytotoxicity. *PLoS ONE*, **2012**, 7, e37051	3.7	26
42	The binding mechanism of a peptidic cyclic serine protease inhibitor. *Journal of Molecular Biology*, **2011**, 412, 235-50	6.5	15
41	Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies. *Biochemical Journal*, **2011**, 438, 39-51	3.8	14
40	Structure of catalytic domain of Matriptase in complex with Sunflower trypsin inhibitor-1. *BMC Structural Biology*, **2011**, 11, 30	2.7	44
39	A fluorescent fatty acid probe, DAUDA, selectively displaces two myristates bound in human serum albumin. *Protein Science*, **2011**, 20, 2095-101	6.3	14
38	A new type of dye-sensitized solar cell with a multilayered photoanode prepared by a film-transfer technique. *Advanced Materials*, **2011**, 23, 2764-8	24	73
37	Substituted zinc phthalocyanine as an antimicrobial photosensitizer for periodontitis treatment. *Journal of Porphyrins and Phthalocyanines*, **2011**, 15, 293-299	1.8	26
36	Structural basis for therapeutic intervention of uPA/uPAR system. *Current Drug Targets*, **2011**, 12, 1729-43	3	27
35	Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs. *Molecular Pharmacology*, **2011**, 80, 585-97	4.3	20

34	Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. *Journal of Biological Chemistry*, **2011**, 286, 43515-26	5.4	27
33	Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. *Journal of Biological Chemistry*, **2011**, 286, 7027-32	5.4	51
32	Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. *Journal of Biological Chemistry*, **2010**, 285, 10982-92	5.4	64
31	Trp2313-His2315 of factor VIII C2 domain is involved in membrane binding: structure of a complex between the C2 domain and an inhibitor of membrane binding. *Journal of Biological Chemistry*, **2010**, 285, 8824-9	5.4	32
30	Expression, purification and characterization of recombinant Jerdonitin, a P-II class snake venom metalloproteinase comprising metalloproteinase and disintegrin domains. *Toxicon*, **2010**, 55, 375-80	2.8	12
29	Identification and biophysical assessment of the molecular recognition mechanisms between the human haemopoietic cell kinase Src homology domain 3 and ALG-2-interacting protein X. *Biochemical Journal*, **2010**, 431, 93-102	3.8	8
28	Pentalysine beta-carbonylphthalocyanine zinc: an effective tumor-targeting photosensitizer for photodynamic therapy. *ChemMedChem*, **2010**, 5, 890-8	3.7	36
27	Crystal structure of a triacylglycerol lipase from Penicillium expansum at 1.3 A determined by sulfur SAD. *Proteins: Structure, Function and Bioinformatics*, **2010**, 78, 1601-5	4.2	13
26	Structural basis of transport of lysophospholipids by human serum albumin. *Biochemical Journal*, **2009**, 423, 23-30	3.8	36
25	Challenges for drug discovery - a case study of urokinase receptor inhibition. *Combinatorial Chemistry and High Throughput Screening*, **2009**, 12, 961-7	1.3	8
24	Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. *Nature Structural and Molecular Biology*, **2008**, 15, 422-3	17.6	95
23	Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. *Structure*, **2008**, 16, 597-606	5.2	185
22	A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography. *Journal of Structural Biology*, **2008**, 162, 40-9	3.4	93
21	X-ray sequence and crystal structure of luffaculin 1, a novel type 1 ribosome-inactivating protein. *BMC Structural Biology*, **2007**, 7, 29	2.7	15
20	Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. *Journal of Structural Biology*, **2007**, 157, 348-55	3.4	149
19	Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. *Journal of Structural Biology*, **2007**, 160, 1-10	3.4	45
18	An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope. *Journal of Molecular Biology*, **2007**, 365, 1117-29	6.5	18
17	Crystal structure of the bovine lactadherin C2 domain, a membrane binding motif, shows similarity to the C2 domains of factor V and factor VIII. *Journal of Molecular Biology*, **2007**, 371, 717-24	6.5	37

16	An open conformation of switch I revealed by Sar1-GDP crystal structure at low Mg2+. *Biochemical and Biophysical Research Communications*, **2006**, 348, 908-15	3.4	13
15	Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator. *Protein Expression and Purification*, **2006**, 49, 71-7	2	11
14	Derivatizable phthalocyanine with single carboxyl group: Synthesis and purification. *Inorganic Chemistry Communication*, **2006**, 9, 313-315	3.1	70
13	Structure of human urokinase plasminogen activator in complex with its receptor. *Science*, **2006**, 311, 656-9	33.3	242
12	Crystal Structure of the Bovine Lactadherin C2 Domain, a Potential Anticoagulant, Shows Similarity to Factor V and Factor VIII.. *Blood*, **2006**, 108, 194-194	2.2	
11	Purification and preliminary crystallographic analysis of a Penicillium expansum lipase. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2005**, 1752, 99-102	4	11
10	Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143). *Acta Crystallographica Section D: Biological Crystallography*, **2005**, 61, 697-700		13
9	Optimization of crystals of an inhibitory antibody of urokinase plasminogen activator receptor (uPAR) with hydrogen peroxide and low protein concentration. *Protein and Peptide Letters*, **2005**, 12, 655-8	1.9	1
8	Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. *Journal of Biological Chemistry*, **2004**, 279, 14338-46	5.4	57
7	Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. *Nature Structural and Molecular Biology*, **2003**, 10, 751-6	17.6	180
6	Protein engineering for crystallization of the GTPase Sar1 that regulates ER vesicle budding. *Acta Crystallographica Section D: Biological Crystallography*, **2002**, 58, 700-3		2
5	Crystal structure of Sar1-GDP at 1.7 A resolution and the role of the NH2 terminus in ER export. *Journal of Cell Biology*, **2001**, 155, 937-48	7.3	133
4	Novel interactions between urokinase and its receptor. *Journal of Biological Chemistry*, **2000**, 275, 24304-12	5.4	27
3	Roles for glycosylation of cell surface receptors involved in cellular immune recognition. *Journal of Molecular Biology*, **1999**, 293, 351-66	6.5	203
2	The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TF.G9 complex. *Journal of Molecular Biology*, **1998**, 275, 873-94	6.5	105
1	Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. *Science*, **1998**, 279, 1166-72	33.3	595